DLD Asset Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

DLD Asset Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-400,000	Closed	-$276K	–	175
2020 Q4	$276K	Buy	400,000 +98,385	+33%	+$210K	0.01%	89
2020 Q3	$679K	Buy	301,615 +101,615	+51%	+$290K	0.02%	73
2020 Q2	$716K	Buy	200,000 +100,000	+100%	+$361K	0.03%	65
2020 Q1	$380K	Sell	100,000 -50,000	-33%	-$165K	0.02%	76
2019 Q4	$461K	Buy	+150,000	New	+$390K	0.02%	85

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

WAM

Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

DLD Asset Management's BMY.RT Position: Q1 2021 in Review

DLD Asset Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 400,000 shares — an estimated $276K sold.

DLD Asset Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $716K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

DLD Asset Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
DLD Asset Management sold 400,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $276K.
DLD Asset Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
DLD Asset Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $716K in Q2 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on DLD Asset Management's 13F filing for Q1 2021, filed 14 May 2021.